{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:05Z","timestamp":1793228345589,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtho.2023.09.1446","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T11:24:14Z","timestamp":1695468254000},"page":"325-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Masahiro","family":"Torasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-801X","authenticated-orcid":false,"given":"Hidehito","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Asao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isana","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Naoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.09.1446_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtho.2023.09.1446_bib2","author":"Howlader"},{"key":"10.1016\/j.jtho.2023.09.1446_bib3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1200\/JCO.1988.6.8.1264","article-title":"Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy","volume":"6","author":"Giaccone","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","article-title":"A\u00a0systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer","volume":"7","author":"Owonikoko","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib5","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.ejca.2014.06.002","article-title":"Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials","volume":"50","author":"Ardizzoni","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2023.09.1446_bib6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.09.1446_bib7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2023.09.1446_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2023.09.1446_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/sim.1333","article-title":"Methods for categorizing a prognostic variable in a multivariable setting","volume":"22","author":"Mazumdar","year":"2003","journal-title":"Stat Med"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.09.1446_bib10","article-title":"MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy","volume":"40","author":"Leventakos","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2023.09.1446_bib11","doi-asserted-by":"crossref","first-page":"S1171","DOI":"10.1016\/j.annonc.2021.08.250","article-title":"1666TiP Phase II study of berzosertib (M6620)\u00a0+ topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250","volume":"32","author":"Thomas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib12","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1997.15.5.2090","volume":"15","author":"Ardizzoni","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.2001.19.6.1743","article-title":"Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer","volume":"19","author":"von Pawel","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib14","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib15","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1200\/JCO.2008.18.1974","article-title":"Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402","volume":"26","author":"Inoue","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2014.01.012","article-title":"A\u00a0single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)","volume":"84","author":"Murakami","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.09.1446_bib17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(16)30104-8","article-title":"Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial","volume":"17","author":"Goto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib18","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib22","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2006.08.4145","article-title":"Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301","volume":"24","author":"Onoda","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.09.1446_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non\u2013small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.annonc.2021.02.025","article-title":"Small cell lung cancer: a slightly less orphan disease after immunotherapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u22c6","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2023.09.1446_bib28","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.09.1446_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/1759-7714.14729","article-title":"Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: a retrospective multicenter study (TOPGAN 2021-01)","volume":"14","author":"Uematsu","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2023.09.1446_bib30","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.21037\/tlcr-22-225","article-title":"Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients","volume":"11","author":"Kushiro","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2023.09.1446_bib31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10637-022-01269-9","article-title":"Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer","volume":"40","author":"Imai","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2023.09.1446_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2009.09.012","article-title":"A\u00a0phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer","volume":"69","author":"Kaira","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.09.1446_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/srep18999","article-title":"Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients","volume":"6","author":"Horita","year":"2016","journal-title":"Sci Rep"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423022566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423022566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:53:06Z","timestamp":1761562386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423022566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1556086423022566"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1446","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.09.1446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}